• Asian Pacific Journal of Cancer Prevention
• /
• 제13권8호
• /
• pp.3917-3925
• /
• 2012

Background: The relationship between postmenopausal hormone therapy (HT) and invasive breast cancer has been extensively investigated, but that with breast carcinoma in situ (BCIS) has received relatively little attention. The aim of our present study was to review and summarize the evidence provided by longitudinal studies on the association between postmenopausal HT use and BCIS risk. Methods: A comprehensive literature search for articles published up to May 2012 was performed. Prior to performing a meta-analysis, the studies were evaluated for publication bias and heterogeneity. Relative risk (RR) or odds ratio (OR) values were calculated using 14 reports (8 case-control studies and 6 cohort studies), published between 1986 and 2012. Results: There was evidence of an association between ever postmenopausal estrogen use and BCIS based on a random-effects model (RR = 1.25, 95% confidence interval (CI) = 1.01, 1.55). However, we found no strong evidence of an association between ever postmenopausal estrogen combined with progesterone use and BCIS using a randomeffects model (RR = 1.55, 95% CI = 0.95, 2.51). Furthermore, our analysis showed a strong association between "> 5 years duration" of estrogen or estrogen combined with progesterone use and BCIS. Furthermore, current use of any HT is associated with increased risk of BCIS in cohort studies. Additional well-designed large studies are now required to validate this association in different populations.

• 여성건강간호학회지
• /
• 제7권4호
• /
• pp.642-656
• /
• 2001

The purpose of this study is to find the difference of the climacteric symptoms and quality of life according to hormone replacement therapy (HRT) in climacteric women. The research design was a descriptive survey with questionaries. A convenience sample of 181 climacteric women aged 45-65 who had climacteric symptoms were selected in Kwangju city, Korea. Sixty-six climacteric women among those subjects were receiving HRT at K university hospital in Kwangju city. Data were collected by the interview with questionaries from Feb 3. 1999 to March 25, 1999. Climacteric symptoms were measured using scores developed by Neugarten(1965) and modified by Park(1989), and the quality of life scale related to climacteric symptoms developed by Hildtich(1996) and modified Kim(1998). Data were analyzed by $x^2$-test, t-test, ANOVA and Pearson's correlation procedures, using SAS/win PC+. The results were as follows ; 1. No statistically significant differences were found between the receiving HRT group and not receiving HRT group in demographic, obstetrical and health related characteristics. 2. There were no significant difference on the climacteric symptoms between the group of women receiving HRT (score 2.4) and the group of women who were not (score 2.6) except psychological area (t= 2.407, p= 0.017). 3. The quality of life of the group of women receiving HRT was significantly higher than that the group of women who were not (t=2.151, p=.032). 4. The quality of life of the group of women receiving HRT were high scores There were significantly high of the quality of life in the vaso-motor change area (t=2.634, p= 0.009), psycho-social change area (t=3.239, p=0.001), and physical change area (t=2.031, p=0,043) in the group of receiving HRT compared to not receiving HRT group. 5. The variables showed significantly differences on the degree of climacteric symptoms of the group of women not receiving HRT were the subjective health state (t=15.81, p=0.000), age (t=7.50, p=0.007), feeling of menopause (t=30.88, p=0,000) and climacteric periods (t=8.66, p=0.003), and receiving HRT were number of para (t=3.95, p=0.050) and feeling of menopause (t=3.94, p=0.050). 6. The variables showed significantly difference on the quality of life of the group of women not receiving HRT were the subjective health state (t=4.14, p=0.044) and feeling of menopause (t=10.86, p=0.001). 7. There were significantly positive correlations between the climacteric symptoms and the quality of life in climacteric women (r=0.512, p=0.000).

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권3호
• /
• pp.1207-1211
• /
• 2015

Background: Breast cancer is by far the most frequent cancer of women (23 % of all cancers), ranking second overall when both sexes are considered together. Contralateral breast cancer (CBC) is becoming an important public health issue because of the increased incidence of primary breast cancer and improved survival. The present communication concerns a study to evaluate the role of various clinico-pathological factors on the occurrence of contralateral breast cancer. Materials and Methods: A detailed analysis was carried out with respect to age, menopausal status, family history, disease stage, surgery performed, histopathology, hormone receptor status, and use of chemotherapy or hormonal therapy. The diagnosis of CBC was confirmed on histopathology report. Relative risk with 95%CI was calculated for different risk factors of contralateral breast cancer development. Results: CBC was found in 24 (4.5%) out of 532 patients. Mean age of presentation was 43.2 years. Family history of breast cancer was found in 37.5% of the patients. There was statistically significant higher rate (83.3%) of CBC in patients in age group of 20-40 years with RR=11.3 (95% CI: 1.4, 89.4, p=0.006) seen in 20-30 years and RR=10.8 (95% CI:1.5-79.6, p=0.002) in 30-40 years as compared to older age of 60-70 years. Risk of development was higher in premenopausal women (RR=8.6, 95% CI: 3.5-21.3, $p{\leq}0.001$). Women with family history of breast cancer had highest rate (20.9%) of CBC (RR=5.4, 95% CI: 2.5-11.6, $p{\leq}0.001$). Use of hormonal therapy in hormone receptor positive patients was protective factor in occurrence of CBC but not significant (RR=0.7, 95% CI: 0.3-1.5, p=0.333). Conclusions: Younger age, premenopausal status, and presence of family history were found to be significant risk factors for the development of CBC. Use of hormonal therapy in hormone receptor positive patients might be protective against occurrence of CBC but did not reach significance.

• Archives of Plastic Surgery
• /
• 제50권1호
• /
• pp.63-69
• /
• 2023

Background An increasing number of nonbinary patients are receiving gender-affirming procedures due to improved access to care. However, the preferred treatments for nonbinary patients are underdescribed. The purpose of this study was to investigate the goals and treatments of nonbinary patients. Methods A retrospective study of patients who self-identified as nonbinary from our institutional Gender Health Program was conducted. Patient demographics, clinical characteristics, surgical goals, and operative variables were analyzed. Results Of the 375 patients with gender dysphoria, 67 (18%) were nonbinary. Over half of the nonbinary patients were assigned male at birth (n = 57, 85%) and nearly half preferred the gender pronoun they/them/theirs (n = 33, 49%). A total of 44 patients (66%) received hormone therapy for an average of 2.5±3.6 years, primarily estrogen (n = 39). Most patients (n = 46, 69%) received or are interested in gender-affirming surgery, of which, almost half were previously on hormone therapy (n = 32, 48%). The most common surgeries completed or desired were facial feminization surgery (n = 15, 22%), vaginoplasty (n = 15, 22%), mastectomy (n = 11, 16%), and orchiectomy (n = 9, 13%). Nonbinary patients who were assigned male at birth (NB-AMAB) were more often treated with hormones compared to nonbinary patients assigned female at birth (NB-AFAB) (72% vs. 30%, p = 0.010). Conversely, patients who were AFAB weremore likely to complete or desire surgical intervention than those who were AMAB (100% vs. 63.0%, p < 0.021). Conclusion Majority of nonbinary patients were assigned male at birth. NB-AFAB patients all underwent surgical treatment, whereas NB-AMAB patients were predominantly treated with hormone therapy.

• Journal of Korean Biological Nursing Science
• /
• 제8권1호
• /
• pp.23-37
• /
• 2006

Purpose: This study was performed to identify climacteric symptoms corresponding to the use of complementary and alternative therapy(CAT) in middle aged women. Method: The subjects of the study were 603women(40-64years) and were chosen by convenient sampling from 1 April to 31 July 2004. The collected data was analyzed using descriptive statics, chi-square, t-test analysis by SPSS/WIN program. Results: 1. It was shown that 63.8% of subjects have utilized one or more types of CAT. 2. It was shown that the most frequently used types are health supplement(40.5%), gold acupuncture(31.2%), acupress(24.7%), hand acupuncture(21.8%) 3. There was significant difference in the using experience CAT by religion(p=.029), job(p=.018), hormone replacement(p=.016), exercise(p=.007), health state(p=.013). 4. There was significant difference in climacteric symptoms(p=.000) corresponding to the using experience of CAT. 5. There was significant difference in climacteric symptoms(p=.028) corresponding to the using experience hand therapy of CAT. Conclusion: We found that middle aged women used CAT more than others populations. Future research examining the determinants of CAT use, incorporating attitudinal and health conditions, as well as clinical efficacy, effectiveness, and health outcome studies of specific CAT therapies are warranted.

• 대한한방부인과학회지
• /
• 제15권4호
• /
• pp.238-246
• /
• 2002

Recently we observed and treated a 49-year-old postmenopausal female with enlarged uterine myoma who taking through the hormone replacement therapy(H.R.T). We regard the cause of this case as insufficiency of kidney-yin(腎陰虛), stagnation or the phlegm and pathologic blood(痰瘀阻滯) and H.R.T. ln general cases, myomas grow in size if estrogen and progesterone is present and do not increase in size if estrogen and progesterone levels are low. So if a woman can get to menopause without having symptoms from the myomas, then it is likely that she will never have problems from the growths that require treatment. But Taking postmenopausal estrogen and progestin replacement therapy can cause myomas to grow. So we recommended her to stop the H.R.T. gave herbal-medicine and acupuncture therapy. Thus we could get a good result as follows. The uterine myomas were significantly declined but no change on it's characters. Hot flush and general conditions were also significantly improved And body weight was lessened for about 4.7kg. But vaginal dryness was appeared, So we planed another therapy for that symptom.

• 혜화의학회지
• /
• 제9권2호
• /
• pp.223-239
• /
• 2001

A literature study on cancer therapy of warm-hot oriental medicine was done, and the results were as follows. 1. In oriental medicine, oncogens are six exopathogens, seven modes of emotion, overwork, pathogenic factors, and especially related with pathologic cold situation. 2. There are many capillaries in tuomr, and because temperature of inner space of tumor is higher than normal organization. Tumor cell has a character which is weak for high temperature. 3. Warm-hot herb drugs have effects of dissipating mass, warming kidney to reinforce yang and dispering, so it has a function of suppressing tumor as well as improving immunity in cancer therapy. 4. In traditional medical books, main prescriptions of cancer therapy are xinzhiyinyanggongjiwan(新製陰陽攻積丸), qianjinxiaoshiwan(千金硝石丸), feiqiwan(肥氣丸), xibenwan(息賁丸), fuliangwan(伏梁丸), beiqiwan, bentunwan(賁豚丸), zengsunwujiwan(增損五積丸), and these are composed of warm-hot herb drugs. 5. In current, the study of warm-hot drugs is progressed in immunological capacity, anti-tumor activity, stimulating bone marrow and regulating hormone secretion. It will be expected that advanced study of these must be accomplished in cancer patients.

• 대한예방의학회:학술대회논문집
• /
• 대한예방의학회 2004년도 제56차 추계 학술대회 연제집
• /
• pp.39-40
• /
• 2004

• 정신신체의학
• /
• 제21권2호
• /
• pp.132-139
• /
• 2013

연구목적 본 연구는 갑상선암 환자에서 인지장애의 발생 빈도와 이에 관계되는 변인을 규명하기 위하여 시행되었다. 방 법 갑상선암으로 진단받고 갑상선전절제술 받은 지 6~12개월 후, 방사성요오드 잔여갑상선제거술을 받기 위해서 입원한 환자 42명을 대상으로 개인력, 병력조사와 우울지수 및 인지기능(Korean Version of the Montreal Cognitive Assessment, 이하 MoCA-K)의 평가를 시행하였다. 결 과 1) 대상 환자 중 MoCA-K 총점이 22점 이하인 환자는 21명(50.0%)이었다. 2) 나이, 교육수준, 방사성 요오드 치료 전 갑상선자극호르몬 농도는 MoCA-K 총점 23점 이상군과 MoCA-K 총점 22점 이하군 간에 통계적으로 유의한 차이가 있었다. 3) MoCA-K 총점과 통계적으로 유의한 연관성이 있는 변인은 나이, 교육수준, 병행질환, 방사성 요오드 치료 전 갑상선자극호르몬 농도, HDRS-17 총점이었다. 결 론 갑상선절제술 후 방사성 요오드 치료를 받기 전 갑상선암 환자에서 인지장애는 50%에서 있었다. 추후, 치료과정의 갑상선암에서 인지장애의 기전을 규명하기 위한 연구가 더 필요하며, 치료 과정의 환자에서 인지장애의 인식과 예방 대책이 요구된다.

• Radiation Oncology Journal
• /
• 제31권3호
• /
• pp.138-146
• /
• 2013

Purpose: To analyze the results of locoregional and systemic therapy in the breast cancer patients with locoregional recurrence (LRR) after mastectomy. Materials and Methods: Seventy-one patients who received radiotherapy for isolated LRR after mastectomy between January 1999 and December 2009 were retrospectively reviewed. Among the 71 patients, 59 (83.1%) underwent wide excision and radiotherapy and 12 (16.9%) received radiotherapy alone. Adjuvant hormonal therapy was given to 45 patients (63.4%). Oncologic outcomes including locoregional recurrence-free survival, disease-free survival (DFS), and overall survival (OS) and prognostic factors were analyzed. Results: Median follow-up time was 49.2 months. Of the 71 patients, 5 (7%) experienced second isolated LRR, and 40 (56%) underwent distant metastasis (DM). The median DFS was 35.6 months, and the 3- and 5-year DFS were 49.1% and 28.6%, respectively. The median OS was 86.7 months, and the 5-year OS was 62.3%. Patients who received hormone therapy together showed better 5-year DFS and OS than the patients treated with locoregional therapy only (31.6% vs. 22.1%, p = 0.036; 66.5% vs. 55.2%, p = 0.022). In multivariate analysis, higher N stage at recurrence was a significant prognostic factor for DFS and OS. Disease free interval (${\leq}30$ months vs. >30 months) from mastectomy to LRR was also significant for OS. The patients who received hormone therapy showed superior DFS and showed trend to better OS. Conclusion: DM was a major pattern of failure after the treatment of LRR after mastectomy. The role of systemic treatment for LRR after mastectomy should be investigated at prospective trials.